Tolerance-Inducing Dose of 3-Nitropropionic Acid Modulates bcl-2 and bax Balance in the Rat Brain: A Potential Mechanism of Chemical Preconditioning

Journal of Cerebral Blood Flow and Metabolism - Tập 20 Số 10 - Trang 1425-1436 - 2000
Ansgar M. Brambrink1,2, Armin Schneider3, Holger Noga2, Andreas Astheimer2, Bernhard Götz3, I Körner1, Oliver Kempski2, Martin Welschof3, Oliver Kempski2
1Department of Anesthesiology, Johannes Gutenberg-University, Mainz, Germany
2Institute of Neurosurgical Pathophysiology, Johannes Gutenberg-University, Mainz, Germany
3Department of Neuroscience, BASF-LYNX Bioscience AG, Heidelberg, Germany

Tóm tắt

Many studies have reported ischemia protection using various preconditioning techniques, including single dose 3-nitropropionic acid (3-NPA), a mitochondrial toxin. However, the cellular signal transduction cascades resulting in ischemic tolerance and the mechanisms involved in neuronal survival in the tolerant state still remain unclear. The current study investigated the mRNA and protein expression of the antiapoptotic bcl-2 and the proapoptotic bax, two antagonistic members of the bcl-2 gene family, in response to a single dose of 3-NPA, to global cerebral ischemia–reperfusion, and to the combination of both 3-NPA-pretreatment and subsequent global cerebral ischemia–reperfusion. Brain homogenates of adult Wistar rats (n = 25) were analyzed for bcl-2 and bax mRNA expression using a new highly sensitive and quantitative polymerase chain reaction (PCR) technique that allows real-time fluorescence measurements of the PCR product (LightCycler; Roche Diagnostics, Mannheim, Germany). Animals for mRNA analysis received 3-NPA (20 mg/kg, intraperitoneal; “chemical preconditioning”) or vehicle (normal saline), and were either observed for 24 plus 3 hours or were subjected to 15 minutes of global cerebral ischemia 24 hours after the pretreatment and observed for 3 hours of reperfusion. Immunohistochemistry was applied to serial brain sections of additional rats (n = 68) to determine amount and localization of the respective Bcl-2 and Bax protein expression in various brain areas. One set of animals was injected with 3-NPA and observed for 3, 12, 24, and 96 hours; a second set was exposed to 15 minutes global cerebral ischemia, 3, 12, and 24 hours reperfusion; and a third set was pretreated with 3-NPA or saline 24 hours before the ischemic brain insult and observed for 96 hours of reperfusion. The authors found single dose 3-NPA treatment to be associated with an elevated bcl-2:bax ratio (increased bcl-2 expression, decreased bax expression), both on the transcriptional (mRNA) and the translational (protein) level. The differential influence of 3-NPA was maintained during early recovery from global cerebral ischemia (3 hours), when 3-NPA pretreated animals showed higher bcl-2 and lower bax mRNA levels compared with rats with saline treatment. Respective changes in protein expression were localized predominately in neurons vulnerable to ischemic damage. Compared with baseline, Bcl-2 protein was significantly higher in surviving neurons at 96 hours after the insult, whereas Bax protein remained unchanged. However, at this late time of postischemic recovery (96 hours), the protein expression pattern of surviving neurons was not different between animals with and without 3-NPA pretreatment. To the authors' knowledge, the current study is the first report on the differential expression of pro-and antiapoptotic genes after a single, nonlethal dose of 3-NPA. The current results suggest alterations in the balance between pro-and antiapoptotic proteins as a potential explanation for the reported protection provided by chemical preconditioning using 3-NPA in rats.

Từ khóa


Tài liệu tham khảo

Abe H, 1996, Acta Neurobiol Exp (Warsz), 56, 3, 10.55782/ane-1996-1096

10.1126/science.281.5381.1322

10.1161/01.STR.29.9.1937

Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

Brambrink AM, 1998, Society of Neuroscience Abstracts, 24, 253

10.1016/S0165-0270(99)00100-4

10.1046/j.1471-4159.1996.67010064.x

10.1074/jbc.274.10.6039

10.1016/0003-2697(87)90021-2

10.1016/S0021-9258(18)50574-3

10.1523/JNEUROSCI.17-16-06165.1997

Garcia-Ruiz C, 1995, Mol Pharmacol, 48, 825

10.1073/pnas.95.6.3168

10.1073/pnas.92.10.4666

10.1073/pnas.95.4.1915

10.1016/0092-8674(93)80066-N

10.1073/pnas.95.9.4997

10.1038/jcbfm.1995.7

10.1097/00004647-200001000-00016

10.1016/0006-8993(90)90189-I

10.1523/JNEUROSCI.15-10-06364.1995

10.1017/S0317167100032212

10.1016/S0361-9230(98)00024-0

10.1016/0896-6273(94)90266-6

10.1016/0092-8674(93)90509-O

10.1097/00004647-199901000-00001

10.1097/00004647-199702000-00007

10.1161/01.CIR.96.5.1598

10.1097/00004647-199703000-00002

10.1016/S0166-2236(99)01435-6

10.1016/0168-0102(94)90026-4

10.1038/20959

10.1161/01.STR.29.6.1240

10.1097/00004647-199907000-00005

10.1126/science.7878463

10.1016/S0304-3940(98)00875-1

10.1097/00004647-199911000-00007

10.2144/97221pf02

10.1038/sj.onc.1201989

10.1073/pnas.90.10.4533

10.1016/S0306-4522(98)00564-8